Skip to content
Austin Top 50
Author:
Plus Therapeutics Inc.
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
March 19, 2026
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
March 13, 2026
←
Previous Page
1
2
3